The case involves an appeal by professional equestrian Amke Stroman against a decision by the Fédération Equestre Internationale (FEI) Tribunal, which imposed a two-year suspension and a fine of CHF 3,000 for a doping violation involving her horse, Celentano 34 (C34). The violation stemmed from the administration of Anabolin Forte, a substance containing nandrolone and estranediol, both classified as banned substances under the FEI’s Equine Anti-Doping and Medication Control Rules (EADMCR). The substance was administered by Stroman’s partner, Ralf Litz, on the advice of their veterinarian while Stroman was away. Although the primary intent was therapeutic, the presence of banned substances in the horse’s system during competition led to the violation.
The Court of Arbitration for Sport (CAS) panel addressed several key issues, including the distinction between banned substances and controlled medication substances, the personal responsibility of the athlete, and the interpretation of relevant regulations. The panel emphasized that banned substances are prohibited at all times, unlike controlled medications, which are only restricted during competition. It rejected Stroman’s argument that the substance could be permitted out of competition if undetectable during events, affirming the FEI’s strict stance on banned substances. The panel also upheld the principle of strict liability, stating that athletes bear personal responsibility for ensuring no banned substances are present in their horses, regardless of veterinary advice or intent.
Stroman argued she bore no significant fault or negligence, as she had relied on her veterinarian’s advice and followed her standard precautionary measures, waiting 30 days before competing. However, the panel found her reliance on third-party advice insufficient to discharge her non-delegable duty of care. It also dismissed her claim that language barriers (the rules not being available in German) excused her from understanding the regulations, given her international competition experience. The panel further rejected mitigating factors such as her clean record and the therapeutic intent behind the administration, as these did not absolve her of responsibility.
The CAS panel concluded that the FEI Tribunal’s decision was correct and proportionate, dismissing Stroman’s appeal and upholding the two-year suspension and fine. The ruling underscores the strict liability principle in anti-doping cases and the high standards expected of athletes in ensuring compliance with anti-doping regulations. The decision also highlights the importance of athletes familiarizing themselves with the rules, irrespective of language barriers or reliance on professional advice. The case serves as a reminder of the stringent measures in place to maintain integrity in equestrian sports.